Related Experiment Video
Updated: Aug 16, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis
Tom Reuvekamp1, Marry Lin2, Lok Lam Ngai3
1Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Amsterdam, Netherlands.
Blood Advances
|August 14, 2026
Summary
Measuring leukemia stem cells (LSC) at diagnosis and during remission significantly impacts outcomes for acute myeloid leukemia (AML) patients. LSC quantification is a crucial prognostic factor for improved clinical practice.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Leukemia stem cells (LSC) are implicated in acute myeloid leukemia (AML) relapse.
- Quantifying LSC at diagnosis and during remission aids risk stratification and residual disease monitoring.
Purpose of the Study:
- To systematically evaluate the prognostic relevance of LSC measurements in AML patients.
- To assess the impact of LSC status on overall survival (OS) and event-free survival (EFS).
Main Methods:
- Conducted a systematic and reconstructed individual patient data meta-analysis.
- Searched for studies reporting OS/EFS in relation to LSC measurements.
- Reconstructed individual patient data from Kaplan-Meier curves.
Main Results:
- Included 56 studies with 44 cohorts (n=7781) for diagnosis and 19 cohorts (n=2006) for remission data.
- Positive LSC status significantly correlated with inferior OS and EFS at both diagnosis and remission.
- Hazard ratios for OS and EFS were consistently higher in LSC-positive patients.
Conclusions:
- Measuring LSC provides significant prognostic value in AML patients.
- LSC frequency is a key prognostic factor that should be integrated into clinical practice.
